Evenamide
Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.
Evenamide
Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.
has abstract
Evenamide (INN) (developmental ...... in the third quarter of 2015.
@en
ATC prefix
CAS number
1092977-61-1
FDA UNII code
ON5S6N53JS
IUPAC name
2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
@en
PubChem
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
48,181,494
Wikipage revision ID
741,603,874
ChemSpiderID
44,208,827
molecular weight
2.7838984e+2
smiles
CCCCOC1=CC=CCCCNCCNC
StdInChIKey
GRHBODILPPXVKN-UHFFFAOYSA-N
hypernym
comment
Evenamide (INN) (developmental ...... in the third quarter of 2015.
@en
label
Evenamide
@en
